Pramlintide Injection

Type 1 diabetes mellitus is an immune-mediated disorder characterized by complete destruction of pancreatic beta-cell function, leaving patients unable to secrete endogenous insulin and amylin, thus requiring lifelong exogenous insulin replacement.

However, insulin monotherapy often fails to effectively control postprandial glucose peaks and may induce hypoglycemia and weight gain. As the only adjunctive therapy approved by the U.S. FDA for type 1 diabetes, Pramlintide Injection is primarily used in patients with suboptimal responses to insulin monotherapy, filling a clinical gap in adjunctive glucose lowering for type 1 diabetes.

Applicable Symptoms:Confirmed type 1 diabetes on long-term basal-bolus insulin therapy, yet with persistent 2-hour postprandial glucose above 10.0 mmol/L or HbA1c ≥ 7.5%, in the absence of contraindications.In such patients, further increasing insulin dosage raises hypoglycemia risk. The product, via its unique mechanism, smooths postprandial glucose peaks without raising insulin requirements, reduces total insulin use, and lowers hypoglycemia risk.

Research findings:In type 1 diabetes patients receiving adjunctive the product with insulin, HbA1c is reduced by 0.1%–0.67%, 1-hour postprandial glucose by 4.4–7 mmol/L, and 2-hour postprandial glucose by 3.6–4.8 mmol/L, significantly improving glycemic variability and attainment of glycemic targets.

Most patients with type 2 diabetes exhibit impaired pancreatic beta-cell function and insulin resistance. Advanced cases often require insulincombination therapy; yet some patients, even on insulin plus oral antidiabetic agents (e.g., sulfonylureas, metformin), fail to achieve ideal glycemic control, especially marked postprandial fluctuations, a major challenge in diabetes management. As a dedicated adjunct to insulin, the product addresses this unmet need in poorly controlled insulin-treated type 2 diabetes.

Applicable Symptoms:Confirmed type 2 diabetes on bolus insulin therapy (with or without metformin and/or sulfonylureas), with persistent 2-hour postprandial glucose above 11.1 mmol/L or HbA1c ≥ 7.0%, in the absence of contraindications.In obese or dyslipidemic type 2 diabetes patients, the satiety-enhancing effect of the product helps reduce caloric intake, supports weight control, improves lipid metabolism, and lowers cardiovascular complication risk.

Clinical data:In insulin-treated type 2 diabetes patients receiving adjunctive the product, HbA1c is reduced by 0.3%–0.62%, 1-hour postprandial glucose by 4.8 mmol/L, and 2-hour postprandial glucose by 3.4 mmol/L. It also reduces insulin requirements, promotes weight loss, and improves glycemic control and quality of life.Compared with GLP-1 receptor agonists and other adjunctive agents, the product is more suitable for patients with higher tolerance to gastrointestinal effects and a primary need for postprandial peak control.

(1) Diabetes with Renal Impairment

Diabetic renal impairment is a common complication. Reduced drug clearance increases accumulation and adverse-event risk, requiring careful antidiabetic selection. The product is primarily renally excreted; however, pharmacokinetic studies show similar clearance in patients with moderate to severe renal impairment (Ccr 20–50 mL/min) compared with healthy subjects, permitting fixed dosing.

Applicable Symptoms:Type 1 or type 2 diabetes with renal impairment (Ccr 20–50 mL/min) and inadequate insulin response, without contraindications.Renal function, glucose, and adverse events (especially hypoglycemia and gastrointestinal effects) must be closely monitored. Pramlintide should be discontinued if renal function worsens (Ccr <20 mL/min) or dialysis is initiated.

(2) Diabetes with Obesity

Obesity is a major risk factor and barrier to glycemic control, often accompanied by insulin resistance. Insulin monotherapy may worsen weight gain, creating a vicious cycle. By enhancing central satiety and reducing food intake, the product aids weight loss, improves insulin resistance, and enables dual management of glucose and body weight.

Applicable Symptoms:Type 1 or type 2 diabetes with obesity (BMI ≥28 kg/m²), inadequate insulin control, and weight management goals.Dose titration, glucose monitoring, diet, and exercise are recommended. Nutritional status should be observed to avoid malnutrition from reduced appetite.

(3) Patients with Marked Postprandial Glycemic Variability

Some diabetic patients (type 1 or 2) have acceptable fasting glucose (4.4–7.0 mmol/L) but extreme postprandial swings: sharp 1–2 hour postprandial elevation followed by rapid decline, causing postprandial hyperglycemia and preprandial hypoglycemia. Insulin monotherapy cannot precisely smooth such fluctuations. The product, by delaying gastric emptying and suppressing postprandial glucagon, stabilizes postprandial peaks and reduces excursion.

Applicable Symptoms:Type 1 or type 2 diabetes with fasting glucose 4.4–7.0 mmol/L but 2-hour postprandial glucose excursion ≥5.0 mmol/L, or frequent postprandial hyperglycemia (≥11.1 mmol/L) and preprandial hypoglycemia (<3.9 mmol/L).Postprandial glucose should be closely monitored, with titration of Pramlintide and insulin doses to achieve stable control.

In addition to core indications, Pramlintide Injection has supplementary roles in optimizing glycemic regimens and addressing complex clinical challenges.

Adjunct to insulin pump therapyIn diabetic patients (primarily type 1) on insulin pumps with persistent postprandial instability, the product administered subcutaneously before meals smooths postprandial glucose, reduces mealtime bolus requirements, lowers hypoglycemia risk, and improves stability. Fixed-ratio 24-hour coadministration significantly improves postprandial hyperglycemia without severe hypoglycemia.

Perioperative glucose control strongly influences surgical outcomes. In patients with poor insulin response and large postprandial swings, short-term Pramlintide use rapidly optimizes control to meet surgical targets and reduce risk. Glucose must be closely monitored; dosing is adjusted by procedure type, and continuation postoperatively depends on oral intake and glycemic control.

Combination therapy in refractory diabetesIn refractory diabetes uncontrolled by multiple agents (insulin + oral drugs) with marked fluctuations, the product may be added for synergistic glucose lowering via its distinct mechanism. Dose titration and adverse-event monitoring are mandatory to avoid interactions.

Hypoglycemia is one of the most common adverse reactions of the product. It mostly occurs during the initial treatment phase, dose titration period, or in combination with insulin, sulfonylureas and other glucose-lowering drugs. Close prevention is required to avoid severe hypoglycemia (such as coma, impaired consciousness).

During treatment with this product, blood glucose should be closely monitored, especially before meals, 1–2 hours after meals, and at bedtime. If hypoglycemic symptoms appear (such as palpitations, tremors, sweating, dizziness, hunger, confusion, etc.), carbohydrates (e.g., glucose tablets, candy, sugar water) must be taken immediately. In the event of severe hypoglycemia, intravenous glucose injection is required.

Special attention should be paid: when this product is used in combination with insulin, the risk of hypoglycemia increases significantly. Therefore, insulin dose adjustment is particularly critical. The pre-meal insulin dose must be reduced by 50% at initiation, and then gradually adjusted according to blood glucose levels; the insulin dose must not be increased without medical advice. For patients also taking sulfonylurea oral antidiabetic drugs, the sulfonylurea dose should be appropriately reduced to further lower the risk of hypoglycemia.

In addition, patients and their families should master the identification of hypoglycemia and emergency treatment measures, carry carbohydrate foods at all times, and avoid driving alone or operating precision instruments to prevent accidents during hypoglycemic episodes. If hypoglycemia occurs frequently, medical attention should be sought promptly to adjust the dose of this product and concomitant medications.